WO2002055101A3 - Storage stable powder compositions of interleukin-4 receptor - Google Patents

Storage stable powder compositions of interleukin-4 receptor Download PDF

Info

Publication number
WO2002055101A3
WO2002055101A3 PCT/US2001/050592 US0150592W WO02055101A3 WO 2002055101 A3 WO2002055101 A3 WO 2002055101A3 US 0150592 W US0150592 W US 0150592W WO 02055101 A3 WO02055101 A3 WO 02055101A3
Authority
WO
WIPO (PCT)
Prior art keywords
powder compositions
interleukin
receptor
storage stable
stable powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/050592
Other languages
French (fr)
Other versions
WO2002055101A2 (en
WO2002055101A9 (en
Inventor
Jayne E. Hastedt
Kirsten M. Cabot
David Gong
Dennis M. Hester
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Inhale Therapeutics Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhale Therapeutics Systems Inc filed Critical Inhale Therapeutics Systems Inc
Priority to JP2002555835A priority Critical patent/JP2004521103A/en
Priority to EP01988413A priority patent/EP1351704B1/en
Priority to CA2432175A priority patent/CA2432175C/en
Priority to AU2002241723A priority patent/AU2002241723A1/en
Priority to DE60127175T priority patent/DE60127175T2/en
Publication of WO2002055101A2 publication Critical patent/WO2002055101A2/en
Publication of WO2002055101A3 publication Critical patent/WO2002055101A3/en
Publication of WO2002055101A9 publication Critical patent/WO2002055101A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides storage stable dry powder compositions of IL-4R. The powder compositions demonstrate superior chemical and physical stability over their solution counterparts, particularly upon storage under varying conditions of temperature and humidity. Moreover, the powders, as prepared, possess good aerosol properties, which are maintained upon storage.
PCT/US2001/050592 2000-12-21 2001-12-21 Storage stable powder compositions of interleukin-4 receptor Ceased WO2002055101A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2002555835A JP2004521103A (en) 2000-12-21 2001-12-21 Storage stable powder composition of interleukin 4 receptor
EP01988413A EP1351704B1 (en) 2000-12-21 2001-12-21 Storage stable powder compositions of interleukin-4 receptor
CA2432175A CA2432175C (en) 2000-12-21 2001-12-21 Storage stable powder compositions of interleukin-4 receptor
AU2002241723A AU2002241723A1 (en) 2000-12-21 2001-12-21 Storage stable powder compositions of interleukin-4 receptor
DE60127175T DE60127175T2 (en) 2000-12-21 2001-12-21 STORAGE-STABLE POWDER COMPOSITIONS WITH INTERLEUKIN-4 RECEPTOR

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25678600P 2000-12-21 2000-12-21
US60/256,786 2000-12-21

Publications (3)

Publication Number Publication Date
WO2002055101A2 WO2002055101A2 (en) 2002-07-18
WO2002055101A3 true WO2002055101A3 (en) 2003-01-30
WO2002055101A9 WO2002055101A9 (en) 2003-10-16

Family

ID=22973579

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/050592 Ceased WO2002055101A2 (en) 2000-12-21 2001-12-21 Storage stable powder compositions of interleukin-4 receptor

Country Status (9)

Country Link
US (4) US6896906B2 (en)
EP (1) EP1351704B1 (en)
JP (3) JP2004521103A (en)
AT (1) ATE355849T1 (en)
AU (1) AU2002241723A1 (en)
CA (1) CA2432175C (en)
DE (1) DE60127175T2 (en)
ES (1) ES2281458T3 (en)
WO (1) WO2002055101A2 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
EP1351704B1 (en) * 2000-12-21 2007-03-07 Nektar Therapeutics Storage stable powder compositions of interleukin-4 receptor
US6777000B2 (en) 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7494669B2 (en) 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
AU2002352836B2 (en) 2001-11-20 2005-09-29 Alkermes, Inc. Improved particulate compositions for pulmonary delivery
WO2003080149A2 (en) 2002-03-20 2003-10-02 Mannkind Corporation Inhalation apparatus
DE10339197A1 (en) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried amorphous powder with low residual moisture and good storage stability
EP1685160A1 (en) * 2003-11-10 2006-08-02 Arriva-Prometic Inc. Dry recombinant human alpha 1-antitrypsin formulation
EP1713441A2 (en) * 2004-02-12 2006-10-25 Nektar Therapeutics Interleukin-13 antagonist powders, spray-dried particles, and methods
DE102004022926A1 (en) * 2004-05-10 2005-12-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powders containing at least one 1,4 O-linked sucrose derivative and process for their preparation
DE102004022928A1 (en) * 2004-05-10 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder containing novel oligosaccharide mixtures and process for their preparation
PL1786784T3 (en) 2004-08-20 2011-04-29 Mannkind Corp Catalysis of diketopiperazine synthesis
KR101644250B1 (en) 2004-08-23 2016-07-29 맨카인드 코포레이션 Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
US7682062B2 (en) * 2004-09-09 2010-03-23 Nanogate Advanced Materials Gmbh Illuminating device
WO2006055950A1 (en) * 2004-11-18 2006-05-26 Nektar Therapeutics Pharmaceutical dry powder formulation on the basis particles comprising multiple active agents
CN104324362B (en) 2005-09-14 2018-04-24 曼金德公司 Method for preparation of drug based on improving affinity of the active agent to crystalline microparticle surfaces
IN2015DN00888A (en) 2006-02-22 2015-07-10 Mannkind Corp
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
DE102006053375A1 (en) * 2006-11-10 2008-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for mixing powders
US20100029832A1 (en) * 2007-01-05 2010-02-04 Board Of Trustees Of Michigan State University Composites comprising polymer and mesoporous silicate
KR20100047866A (en) * 2007-07-11 2010-05-10 애로반스, 인코포레이티드 Pharmaceutical polypeptide dry powder aerosol formulation and method of preparation
WO2009136541A1 (en) * 2008-05-09 2009-11-12 アークレイ株式会社 Method for production of insoluble carrier particle, insoluble carrier particle, measurement reagent, sample analysis tool, and immunology turbidimetric method
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2929343T3 (en) 2008-06-13 2022-11-28 Mannkind Corp Suction Actuated Dry Powder Inhaler for Drug Delivery
KR101628410B1 (en) 2008-06-20 2016-06-08 맨카인드 코포레이션 An interactive apparatus and method for real-time profiling of inhalation efforts
TWI614024B (en) 2008-08-11 2018-02-11 曼凱公司 Ultra-fast use of insulin
PE20110543A1 (en) 2008-08-15 2011-08-04 Ironwood Pharmaceuticals Inc SOLID ORAL FORMULATION INCLUDING LINACHLOTIDE, CALCIUM CATION AND LEUCINE
EP2331077A2 (en) * 2008-09-04 2011-06-15 Ironwood Pharmaceuticals, Inc. Stable forlulation comprising therapeutic polypeptides for oral administration
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2379511B1 (en) 2008-12-29 2014-12-17 MannKind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
DK2405963T3 (en) 2009-03-11 2013-12-16 Mannkind Corp DEVICE, SYSTEM AND PROCEDURE FOR MEASURING RESISTANCE IN AN INHALATOR
CN104721825B (en) 2009-06-12 2019-04-12 曼金德公司 With the diketopiperazine particle for determining specific surface area
CA2770077A1 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
UA108636C2 (en) 2010-02-17 2015-05-25 PEPTIDE
IL223742A (en) 2010-06-21 2016-06-30 Mannkind Corp Dry powder inhaler and composition therefor
EP2603232B1 (en) 2010-08-11 2019-09-25 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
AU2012236150B2 (en) 2011-04-01 2016-03-31 Mannkind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
MX347354B (en) 2011-08-17 2017-04-24 Ironwood Pharmaceuticals Inc TREATMENTS FOR GASTROINTESTINAL DISORDERS.
BR112014009686A2 (en) 2011-10-24 2018-08-07 Mannkind Corp Inhalable analgesic composition, dry powder and method for treating pain
US8753643B1 (en) 2012-04-11 2014-06-17 Life-Science Innovations, Llc Spray dried compositions and methods of use
CN104619369B (en) 2012-07-12 2018-01-30 曼金德公司 Dry powder drug delivery systems and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
JP6649246B2 (en) * 2013-03-14 2020-02-19 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Compositions for sustained release delivery of proteins and methods for stabilizing proteins during the manufacturing process
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
MX375448B (en) 2013-07-18 2025-03-06 Mannkind Corp HEAT-STABLE DRY POWDER PHARMACEUTICAL COMPOSITIONS AND METHODS.
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
MX392636B (en) 2014-10-31 2025-03-24 Glaxosmithkline Ip Dev Ltd POWDER FORMULATION.
EP4345110A3 (en) * 2016-09-22 2024-06-12 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599905A (en) * 1988-10-31 1997-02-04 Immunex Corporation Interleukin-4 receptors
WO2001008708A2 (en) * 1999-07-29 2001-02-08 Case Western Reserve University Enhanced delivery via serpin enzyme complex receptor ligands
WO2001062272A2 (en) * 2000-02-25 2001-08-30 Immunex Corporation Soluble tumor necrosis factor receptor and il-4 inhibitor for the treatment of medical disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211769A (en) * 1977-08-24 1980-07-08 Takeda Chemical Industries, Ltd. Preparations for vaginal administration
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
IT1206302B (en) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca URINARY FOLLICLE-STIMULATING HORMONE
WO1992014449A1 (en) * 1991-02-20 1992-09-03 Nova Pharmaceutical Corporation Controlled release microparticulate delivery system for proteins
DE69230613T2 (en) * 1991-07-02 2000-12-28 Inhale Inc METHOD AND DEVICE FOR DISPENSING MEDICINES IN AEROSOL FORM
DE4322330A1 (en) 1992-08-31 1994-03-03 Behringwerke Ag Use of the IL-4 receptor for the therapy, prophylaxis and diagnosis of allergic, viral, parasitic and bacterial diseases as well as fungal infections
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
NZ263102A (en) * 1993-03-19 1997-05-26 Immunex Corp Pharmaceutical compositions comprising a ligand protein such as interleukin-4 and a soluble receptor protein that binds thereto
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
MX9605717A (en) * 1994-05-18 1998-05-31 Inhale Therapeutic Syst Methods and compositions for the dry powder formulation of interferons.
NZ292980A (en) * 1994-09-29 1999-02-25 Andaris Ltd Smooth, spherical water-soluble microparticles as therapeutic or diagnostic vehicles
EP1351704B1 (en) * 2000-12-21 2007-03-07 Nektar Therapeutics Storage stable powder compositions of interleukin-4 receptor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599905A (en) * 1988-10-31 1997-02-04 Immunex Corporation Interleukin-4 receptors
WO2001008708A2 (en) * 1999-07-29 2001-02-08 Case Western Reserve University Enhanced delivery via serpin enzyme complex receptor ligands
WO2001062272A2 (en) * 2000-02-25 2001-08-30 Immunex Corporation Soluble tumor necrosis factor receptor and il-4 inhibitor for the treatment of medical disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CURRENT OPINION IN CARDIOVASCULAR, PULMONARY & RENAL INVESTIGATIONAL DRUG (1999), 1(4), 526-531, 1999 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; LANGE, ROBERT: "Interleukin 4 receptor Immunex Corp", XP002216866, retrieved from STN Database accession no. 132:220921 CA *

Also Published As

Publication number Publication date
US7172768B2 (en) 2007-02-06
JP2012153719A (en) 2012-08-16
US7449201B2 (en) 2008-11-11
US20090035264A1 (en) 2009-02-05
ES2281458T3 (en) 2007-10-01
US20070122354A1 (en) 2007-05-31
EP1351704A2 (en) 2003-10-15
EP1351704B1 (en) 2007-03-07
US20050129625A1 (en) 2005-06-16
US6896906B2 (en) 2005-05-24
JP2009102362A (en) 2009-05-14
US7767198B2 (en) 2010-08-03
JP2004521103A (en) 2004-07-15
CA2432175C (en) 2010-08-10
DE60127175T2 (en) 2007-11-08
AU2002241723A1 (en) 2002-07-24
CA2432175A1 (en) 2002-07-18
WO2002055101A2 (en) 2002-07-18
US20020176846A1 (en) 2002-11-28
DE60127175D1 (en) 2007-04-19
WO2002055101A9 (en) 2003-10-16
ATE355849T1 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
WO2002055101A3 (en) Storage stable powder compositions of interleukin-4 receptor
AU2001262475A1 (en) Novel compounds of the n-acylamino-amide family, compositions comprising same, and uses
EP2036943A3 (en) Compositions containing fluorine substituted olefins
TW200420686A (en) Polyamide powder with long-lasting, consistently good flowability
CA2390649A1 (en) 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them
WO2001032646A3 (en) Sulfonamide derivatives
EA200301275A1 (en) CAPSULES FOR INHALATION
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
TR199902863T2 (en) T�bbi aerosol �r�nleri.
WO2006136723A3 (en) Make-up compositions for keratinous materials
EP2272946A3 (en) Minicell compositions and methods
AU2002336300A1 (en) Fluororesin based powder coating composition
WO2001098245A3 (en) Triphenyl compounds as interleukin-4 antagonists
WO2004007664A3 (en) Nucleic acid vectors
WO2007024961A3 (en) Bazedoxifene acetate formulations and manufacturing process thereof
WO2002076176A3 (en) Mixtures containing 1,1,1,3,3-pentafluoropropane and 1,1,1,3,3-pentafluorobutane
WO2002067675A3 (en) Substituted 4,5-dihydro-1,2,4-triazin-6-ones, 1,2,4-triazin-6-ones, and their use as fungicides and insecticides
WO2003000011A3 (en) Novel pyridopyrimidines and uses thereof
AU2002217890A1 (en) Low gloss powder coating compositions
EP1607097A3 (en) Stabilized compositions containing an oxygen-labile agent
WO2006043104A3 (en) Flexible pad for preparing a beverage
WO2007069254A3 (en) POLYMORPHS AND AMORPHOUS FORMS OF 5-AMINO-l-[2,6- DICHLORO-4-(TRIFLUOROMETHYL)PHENYL]-4- [(TRIFLUOROMETHYL)SULFINYL]-IH-PYRAZOLE-3-CARBONITRILE
HUP0402183A2 (en) Liquid yeast compositions
WO2004064517A3 (en) Termiticide compositions
WO2000056304A3 (en) Anti-inflammatory uses of manzamines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2432175

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002555835

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001988413

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001988413

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGES 1/2-2/2, DRAWINGS, REPLACED BY NEW PAGES 1/2-2/2; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001988413

Country of ref document: EP